[Correction added on 21 April 2014, after first online publication: the title has been shortened].
Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow's milk allergy
Article first published online: 6 JAN 2014
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Pediatric Allergy and Immunology
Volume 25, Issue 3, pages 227–235, May 2014
How to Cite
Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow's milk allergy. Pediatr Allergy Immunol 2014: 25: 227–235., , , , , , , , , .
- Issue published online: 21 APR 2014
- Article first published online: 6 JAN 2014
- Manuscript Accepted: 3 DEC 2013
- National Institutes of Health. Grant Number: #AI-44236
- Academy of Finland
- Center of Excellence in Cancer Genetics Research. Grant Number: 125826
- Helsinki University Central Hospital Research Funds
- antibody affinity;
- cow's milk allergy;
- oral immunotherapy;
Oral immunotherapy (OIT) with cow's milk (CM) has been reported to induce a number of specific antibody responses, but these remain to be fully characterized. Our objective was to explore whether IgE and IgG4 epitope binding profiles could predict the risk of side effects during CM OIT.
The study population consisted of 32 children (6–17 yr of age) with CM allergy: 26 children who successfully completed OIT and six children who discontinued therapy due to adverse reactions. We investigated sera drawn before and after OIT. We analyzed specific IgE and IgG4 binding to CM protein-derived peptides with a microarray-based immunoassay. Antibody binding affinity was analyzed with a competition assay where CM proteins in solution competed with peptides printed on the microarray.
IgE binding to CM peptides decreased and IgG4 binding increased following the OIT in children who attained desensitization. Compared with children who successfully completed OIT, those who discontinued OIT due to adverse reactions developed increased quantities and affinity of epitope-specific IgE antibodies and a broader diversity of IgE and IgG4 binding, but less overlap in IgE and IgG4 binding to CM peptides.
Detailed analysis of IgE and IgG4 binding to CM peptides may help in predicting whether CM OIT will be tolerated successfully. It may thus improve the safety of the therapy.